Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.
Reasons to Purchase
Quantify the future size of the antidiabetics market and identify opportunities for new products.
Learn how product expiries will shape the antidiabetics market.
Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.
(0 items)
